Innate Pharma (IPHA)
NASDAQ:IPHA

Innate Pharma (IPHA) Technical Analysis

79 Followers

Technical Sentiment

Overall Consensus
Strong Sell
2Bullish
6Neutral
14Bearish
Technical Analysis Consensus
Neutral
2Bullish
6Neutral
2Bearish
Moving Average Consensus
Strong Sell
0Bullish
0Neutral
12Bearish
Innate Pharma’s (IPHA) Moving Averages Convergence Divergence (MACD) indicator is -0.04, suggesting Innate Pharma is a Sell.
Innate Pharma’s (IPHA) 20-Day exponential moving average is 2.17, while Innate Pharma’s (IPHA) share price is $2.13, making it a Sell.
Innate Pharma’s (IPHA) 50-Day exponential moving average is 2.29, while Innate Pharma’s (IPHA) share price is $2.13, making it a Sell.

Innate Pharma (IPHA) Pivot Points

Jul 28, 2024, 04:24 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.92
2.00
2.05
2.13
2.18
2.26
2.31
Fibonacci
2.00
2.05
2.08
2.13
2.18
2.21
2.26
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Innate Pharma (IPHA) Moving Averages

Jul 28, 2024, 04:24 PM
Period
Simple
Exponential
MA5
2.17Sell
2.15Sell
MA10
2.16Sell
2.16Sell
MA20
2.13Sell
2.17Sell
MA50
2.38Sell
2.29Sell
MA100
2.44Sell
2.40Sell
MA200
2.50Sell
2.50Sell
Innate Pharma’s (IPHA) 10-Day exponential moving average is 2.16, while Innate Pharma’s (IPHA) share price is $2.13, making it a Sell.
Innate Pharma’s (IPHA) 100-Day exponential moving average is 2.40, while Innate Pharma’s (IPHA) share price is $2.13, making it a Sell.
Innate Pharma’s (IPHA) stock price is $2.13 and Innate Pharma’s (IPHA) 50-day simple moving average is 2.38, creating a Sell signal.
Innate Pharma’s (IPHA) stock price is $2.13 and Innate Pharma’s (IPHA) 100-day simple moving average is 2.44, creating a Sell signal.
Innate Pharma’s (IPHA) stock price is $2.13 and Innate Pharma’s (IPHA) 200-day simple moving average is 2.50, creating a Sell signal.

Innate Pharma (IPHA) Technical Indicators

Jul 28, 2024, 04:24 PM
Name
Value
Implied Action
RSI (14)
46.16
Neutral
STOCH (9,6)
29.53
Neutral
STOCHRSI (14)
33.49
Neutral
MACD (12,26)
-0.04
Sell
ADX (14)
21.99
Neutral
Williams %R
-78.13
Buy
CCI (14)
4.70
Neutral
ATR (14)
0.13
-
Ultimate Oscillator
30.50
Neutral
ROC
-0.93
Sell
Innate Pharma’s (IPHA) Relative Strength Index (RSI) is 46.16, creating a Neutral signal.
Innate Pharma’s (IPHA) Trend Strength Indicator (ADX) is 21.99, creating a Neutral signal.
Innate Pharma’s (IPHA) Commodity Channel Index (CCI) is 4.70, creating a Neutral signal.
Innate Pharma’s (IPHA) Price Rate of Change (ROC) is -0.93, creating a Sell signal.

FAQ

Is IPHA a Buy, Hold, or Sell?
Based on IPHA’s technical indicators, IPHA is a Strong Sell.
    What is IPHA’s RSI (14)?
    IPHA’s RSI (14) is 46.16, which suggests IPHA is a Neutral.
      What is IPHA’s MACD?
      IPHA’s MACD is -0.04, which suggests IPHA is a Sell.
        What is IPHA’s 5-day moving average?
        IPHA’s 5-day moving average is 2.17, which suggests IPHA is a Sell.
          What is IPHA’s 20-day moving average?
          IPHA 20-day moving average is 2.13, which suggests IPHA is a Sell.
            What is IPHA’s 50-day moving average?
            IPHA’s 50-day moving average is 2.38, which suggests IPHA is a Sell.
              What is IPHA’s 200-day moving average?
              IPHA’s 200-day moving average is 2.50, which suggests IPHA is a Sell.
                What is IPHA’s Williams % R (14)?
                IPHA’s Williams % R (14) is -78.13, which suggests IPHA is a Buy.
                  What is IPHA’s CCI (14)?
                  IPHA’s CCI (14) is 4.70, which suggests IPHA is a Neutral.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis